Dynavax Technologies Future Growth
Future criteria checks 4/6
Dynavax Technologies is forecast to grow earnings and revenue by 38.5% and 17% per annum respectively while EPS is expected to grow by 36.1% per annum.
Key information
38.5%
Earnings growth rate
36.1%
EPS growth rate
Biotechs earnings growth | 28.8% |
Revenue growth rate | 17.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 07 Aug 2024 |
Recent future growth updates
Recent updates
Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 381 | 68 | 69 | 99 | 4 |
12/31/2025 | 336 | 51 | 40 | 70 | 5 |
12/31/2024 | 282 | 26 | 2 | 25 | 5 |
6/30/2024 | 250 | 17 | 35 | 39 | N/A |
3/31/2024 | 236 | 9 | 53 | 56 | N/A |
12/31/2023 | 232 | -6 | 96 | 101 | N/A |
9/30/2023 | 361 | 61 | 118 | 122 | N/A |
6/30/2023 | 459 | 111 | 147 | 152 | N/A |
3/31/2023 | 656 | 236 | 134 | 141 | N/A |
12/31/2022 | 723 | 293 | 56 | 63 | N/A |
9/30/2022 | 733 | 320 | 140 | 148 | N/A |
6/30/2022 | 674 | 228 | 142 | 153 | N/A |
3/31/2022 | 470 | 104 | 238 | 247 | N/A |
12/31/2021 | 439 | 72 | 326 | 336 | N/A |
9/30/2021 | 258 | -39 | 192 | 199 | N/A |
6/30/2021 | 163 | -6 | 101 | 105 | N/A |
3/31/2021 | 113 | -62 | -31 | -27 | N/A |
12/31/2020 | 40 | -75 | -103 | -92 | N/A |
9/30/2020 | 38 | -97 | -112 | -100 | N/A |
6/30/2020 | 35 | -138 | -115 | -94 | N/A |
3/31/2020 | 40 | -129 | -136 | -108 | N/A |
12/31/2019 | 35 | -156 | -151 | -121 | N/A |
9/30/2019 | 30 | -159 | -161 | -132 | N/A |
6/30/2019 | 21 | -163 | -166 | -144 | N/A |
3/31/2019 | 14 | -160 | -157 | -141 | N/A |
12/31/2018 | 8 | -159 | -146 | -131 | N/A |
9/30/2018 | 3 | -146 | -130 | -115 | N/A |
6/30/2018 | 1 | -128 | -110 | -99 | N/A |
3/31/2018 | 0 | -109 | N/A | -82 | N/A |
12/31/2017 | 0 | -95 | N/A | -78 | N/A |
9/30/2017 | 8 | -89 | N/A | -86 | N/A |
6/30/2017 | 8 | -102 | N/A | -97 | N/A |
3/31/2017 | 10 | -111 | N/A | -105 | N/A |
12/31/2016 | 11 | -112 | N/A | -107 | N/A |
9/30/2016 | 4 | -118 | N/A | -103 | N/A |
6/30/2016 | 5 | -113 | N/A | -97 | N/A |
3/31/2016 | 4 | -108 | N/A | -96 | N/A |
12/31/2015 | 4 | -107 | N/A | -93 | N/A |
9/30/2015 | 6 | -102 | N/A | -88 | N/A |
6/30/2015 | 7 | -102 | N/A | -88 | N/A |
3/31/2015 | 8 | -103 | N/A | -87 | N/A |
12/31/2014 | 11 | -91 | N/A | -74 | N/A |
9/30/2014 | 12 | -90 | N/A | -69 | N/A |
6/30/2014 | 12 | -76 | N/A | -58 | N/A |
3/31/2014 | 13 | -68 | N/A | -51 | N/A |
12/31/2013 | 11 | -75 | N/A | -59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVAX's forecast earnings growth (38.5% per year) is above the savings rate (2.5%).
Earnings vs Market: DVAX's earnings (38.5% per year) are forecast to grow faster than the US market (15.2% per year).
High Growth Earnings: DVAX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DVAX's revenue (17% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: DVAX's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time